Genomic profiling of mitochondrion-rich breast carcinoma: chromosomal changes may be relevant for mitochondria accumulation and tumour biology
Authors:
- Dario de BiaseDario de Biase
- Maryou B. K. LambrosMLMaryou B. K. Lambros
- Rachael NatrajanRNRachael Natrajan
- Alan MackayAMAlan Mackay
- Ivana KurelacIKIvana Kurelac
- Alan AshworthAAAlan Ashworth
- Jorge S. Reis-FilhoJRJorge S. Reis-Filho
- 21 April 2011
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 132 (1) , 15-28
Abstract
Oncocytic carcinomas are composed of mitochondrion-rich cells. Though recognised by the WHO classification as a histological special type of breast cancer, their status as a discrete pathological entity remains a matter of contention. Given that oncocytic tumours of other anatomical sites display distinct clinico-pathological and molecular features, we sought to define the molecular genetic features of mitochondrion-rich breast tumours and to compare them with a series of histological grade- and oestrogen receptor status-matched invasive ductal carcinomas of no special type. Seventeen mitochondrion-rich breast carcinomas, including nine bona fide oncocytic carcinomas, were profiled with antibodies against oestrogen, progesterone and androgen receptors, HER2, Ki67, GCDFP-15, chromogranin, epithelial membrane antigen, cytokeratin 7, cytokeratin 14, CD68 and mitochondria antigen. These tumours were microdissected and DNA extracted from samples with >70% of tumour cells. Fourteen cases yielded DNA of sufficient quality/quantity and were subjected to high-resolution microarray comparative genomic hybridisation analysis. The genomic profiles were compared to those of 28 grade- and oestrogen receptor status-matched invasive ductal carcinomas of no special type. Oncocytic and other mitochondrion-rich tumours did not differ significantly between themselves. As a group, mitochondrion-rich carcinomas were immunophenotypically heterogenous. Recurrent copy number changes were similar to those described in unselected breast cancers. However, unsupervised and supervised analysis identified a subset of mitochondrion-rich cancers, which often displayed gains of 11q13.1-q13.2 and 19p13. Changes in the latter two chromosomal regions have been shown to be associated with oncocytic tumours of the kidney and thyroid, respectively, and host several nuclear genes with specific mitochondrial function. Our results indicate that in a way akin to oncocytic tumours of other anatomical sites, at least a subset of mitochondrion-rich breast carcinomas may be underpinned by a distinct pattern of chromosomal changes potentially relevant for mitochondria accumulation and constitute a discrete molecular entity.Keywords
This publication has 53 references indexed in Scilit:
- Telomere dysfunction induces metabolic and mitochondrial compromiseNature, 2011
- SDHA is a tumor suppressor gene causing paragangliomaHuman Molecular Genetics, 2010
- Estrogen Receptor Status Could Modulate the Genomic Pattern in Familial and Sporadic Breast CancerClinical Cancer Research, 2007
- Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumorsProceedings of the National Academy of Sciences, 2007
- The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer SubtypesClinical Cancer Research, 2007
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- Novel patterns of genome rearrangement and their association with survival in breast cancerGenome Research, 2006
- Mitochondrial DNA Somatic Mutations (Point Mutations and Large Deletions) and Mitochondrial DNA Variants in Human Thyroid PathologyThe American Journal of Pathology, 2002
- Mitochondrial DNA ?common? deletion in H rthle cell lesions of the thyroidThe Journal of Pathology, 2000
- pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upHistopathology, 1991